Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis

被引:0
作者
Massimo Breccia
Luigiana Luciano
Novella Pugliese
Elena Rossi
Mario Tiribelli
Emilia Scalzulli
Massimiliano Bonifacio
Bruno Martino
Roberto Latagliata
Giulia Benevolo
Giovanni Caocci
Gianni Binotto
Vincenzo Martinelli
Michele Cavo
Fabrizio Pane
Valerio De Stefano
Robin Foà
Francesca Palandri
机构
[1] Sapienza University,Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I
[2] Federico II University,Institute of Hematology
[3] Fondazione Policlinico A. Gemelli IRCCS,Division of Hematology and BMT, Department of Medical Area
[4] Catholic University,Department of Medicine, Section of Hematology
[5] University of Udine,Division of Hematology
[6] University of Verona,Division of Hematology
[7] Azienda Ospedaliera ‘Bianchi Melacrino Morelli’,Department of Medical Sciences and Public Health, Hematology and Transplant Center, Businco Hospital
[8] Città della Salute e della Scienza Hospital,Unit of Hematology and Clinical Immunology
[9] University of Cagliari,Institute of Hematology “L. and A. Seràgnoli”
[10] University of Padova,undefined
[11] Sant’Orsola-Malpighi University Hospital,undefined
来源
Annals of Hematology | 2019年 / 98卷
关键词
Myelofibrosis; Ruxolitinib; Hydroxyurea; Efficacy;
D O I
暂无
中图分类号
学科分类号
摘要
Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomegaly and symptoms. During treatment, as rare conditions, leukocytosis and/or thrombocytosis could develop and the management of these situations is not well established. We report here 53 myelofibrosis patients that received a combination of hydroxyurea and ruxolitinib because of uncontrolled myeloproliferation. Both drugs were administered outside clinical trials. At 48 weeks, a significant reduction in leucocyte and platelet counts was observed (p = 0.02 and p = 0.04, respectively). Additionally, the spleen volume decreased from a median value of 10 cm below the left costal margin (range, 0–10) to 6 cm (range, 0–15). The rate of spleen response increased from 14% at the start of the combination to 45% after 48 weeks. The safety profile of the combination was consistent with that observed with ruxolitinib single agent. These data require further confirmation in large cohorts of patients prospectively assessed.
引用
收藏
页码:1933 / 1936
页数:3
相关论文
共 52 条
[51]  
Mocci C(undefined)undefined undefined undefined undefined-undefined
[52]  
La Nasa G(undefined)undefined undefined undefined undefined-undefined